Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Hydromorphone hydrochloride
Janssen-Cilag Pty Ltd
Medicine Registered
JURNISTA ® 1 JURNISTA ® _Hydromorphone hydrochloride _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about JURNISTA prolonged-release tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking JURNISTA against the benefits this medicine is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING JURNISTA, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT JURNISTA IS TAKEN FOR JURNISTA is taken to relieve moderate to severe pain, which requires strong painkillers. JURNISTA is only for patients with chronic, around the clock pain that is moderate to severe and expected to be long lasting. JURNISTA should not usually be the first medicine prescribed for your pain. JURNISTA prolonged-release tablets contain a medicine called hydromorphone hydrochloride. This strong pain reliever belongs to a group of medicines known as opioid analgesics. Hydromorphone hydrochloride relieves pain by blocking the nerves that recognise pain messages from the body._ _ Your doctor may have prescribed JURNISTA for another reason. Ask your doctor if you have any questions about why this medicine has been prescribed for you. BEFORE YOU TAKE JURNISTA _WHEN YOU MUST NOT TAKE IT _ DO NOT TAKE JURNISTA IF YOU: • have an allergy to hydromorphone hydrochloride or any of the ingredients. See PRODUCT DESCRIPTION at the end of this leaflet for a list of ingredients. • have been diagnosed with serious narrowing of the stomach and/or intestine (bowel) • ha Read the complete document
JURNISTA ® PROLONGED-RELEASE TABLETS PRODUCT INFORMATION NAME OF THE MEDICINE Hydromorphone hydrochloride DESCRIPTION Hydromorphone hydrochloride has four asymmetric carbon atoms (C 5 , C 9 , C 13 and C 14 ), with a specific rotation (20°C, 589 nm) of –136.5° to –138.5°. No cis-trans isomerism or threo-erythro isomerism was detected. No other isomers are known. Hydromorphone hydrochloride has the following structural formula: 4,5 α-epoxy-3-hydroxy-17-methyl-morphinan-6-one hydrochloride CAS: 71-68-1 C 17 H 19 NO 3 .HCl MW: 321.8 Hydromorphone hydrochloride is freely soluble in water, very slightly soluble in ethanol and practically insoluble in methylene chloride. JURNISTA tablets have been formulated using the OROS ® osmotic pump (push-pull) bilayer tablet with a semi-permeable cellulose acetate coating that controls the rate at which water is absorbed into the tablet after it has been swallowed. A laser-drilled hole on the drug side of the tablet allows the dissolved/suspended drug to be released from the tablet at a controlled rate as it passes through the gastrointestinal tract. The JURNISTA tablet is non-deformable and does not appreciably change in shape in the GI tract; patients should be advised not to be alarmed if they notice what appears to be the JURNISTA tablet in their stools, as it is simply the non-dissolvable shell. JURNISTA is available as prolonged-release tablets containing 4, 8, 16, 32 and 64 mg hydromorphone hydrochloride. JURNISTA tablets contain the inactive ingredients: CCDS Dec12 2 jcpjurni10313 _Coated tablet core:_ polyethylene oxide, povidone, magnesium stearate, butylated hydroxytoluene (E321), polyethylene oxide, sodium chloride, hypromellose, iron oxide black (E172), lactose anhydrous, cellulose acetate, macrogo Read the complete document